✦ LIBER ✦

Seventeen years experience with accelerated radiotherapy for carcinoma of the breast

✍ Scribed by Vladimir H. Svoboda; Julian Krawczyk; Alicja Krawczyk

Publisher: Elsevier Science
Year: 1992
Tongue: English
Weight: 765 KB
Volume: 24
Category: Article
ISSN: 0360-3016
DOI: 10.1016/0360-3016(92)91023-g

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Carcinoma of the male breast: A 30 year

Carcinoma of the male breast: A 30 year experience

✍ Bernard Roswit; Herbert Edlis; Enio Solisio 📂 Article 📅 1977 🏛 Elsevier Science 🌐 English ⚖ 166 KB

15 years experience with carcinoma of th

15 years experience with carcinoma of the endometrium

✍ S. Kalnicki; S.G. Ariathurai; F. Mincer; C. Botstein; G. Zacharopoulos 📂 Article 📅 1978 🏛 Elsevier Science 🌐 English ⚖ 88 KB

Radiotherapy of unresectable pancreatic

Radiotherapy of unresectable pancreatic carcinoma: A six year experience with 104 patients

✍ Richard Whittington; Ralph R. Dobelbower; Mohammed Mohiuddin; Francis E. Rosato; 📂 Article 📅 1981 🏛 Elsevier Science 🌐 English ⚖ 669 KB

Subclavian artery occlusion after radiot

Subclavian artery occlusion after radiotherapy for carcinoma of the breast

✍ Moshe Hashmonai; Amir Elami; Abraham Kuten; Chaim Lichtig; Shlomo Torem 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 443 KB 👁 2 views

Carcinoma of the oral tongue and floor o

Carcinoma of the oral tongue and floor of mouth: Fifteen years' experience with linear accelerator therapy

✍ Edward H. Gilbert; Don R. Goffinet; Malcolm A. Bagshaw 📂 Article 📅 1975 🏛 John Wiley and Sons 🌐 English ⚖ 520 KB

Carcinoma of the nasopharynx. Eighteen y

Carcinoma of the nasopharynx. Eighteen years' experience with megavoltage radiation therapy

✍ Richard T. Hoppe; Don R. Goffinet; Malcolm A. Bagshaw 📂 Article 📅 1976 🏛 John Wiley and Sons 🌐 English ⚖ 561 KB

From 1956 through 1973, 82 patients with carcinoma of the nasopharynx received high dose megavoltage radiation therapy a t Stanford University. The actuarial disease-free (NED) survival was 62% a t 5 years and 56% a t 10 years. The NED survivals a t 5 years for patients with T I , T2, and T3 lesion